2013 discharge: European Medicines Agency (EMA)

This dossier is the 2013 discharge for the European Medicines Agency (EMA). Amendments propose granting or postponing discharge and the closure of accounts, note that a large share of the Agency's budget comes from industry fees, raise transparency of funding, recruitment and declarations of interests of scientific committee members, and criticise the Agency's broad view of commercial confidential information and its clinical trial data publication policies.